MARKET

VTVT

VTVT

Vtv Therapeutics
NASDAQ
33.87
-2.62
-7.18%
After Hours: 33.99 +0.12 +0.35% 18:15 02/13 EST
OPEN
35.05
PREV CLOSE
36.49
HIGH
35.77
LOW
33.77
VOLUME
5.52K
TURNOVER
--
52 WEEK HIGH
44.00
52 WEEK LOW
14.00
MARKET CAP
133.39M
P/E (TTM)
-10.1938
1D
5D
1M
3M
1Y
5Y
1D
vTv Therapeutics Presents at TD Cowen Health Care Conference
Reuters · 1d ago
vTv Therapeutics to Participate in Upcoming Investor Conferences
Barchart · 1d ago
Weekly Report: what happened at VTVT last week (0202-0206)?
Weekly Report · 5d ago
Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS)
TipRanks · 02/03 02:40
vTv Therapeutics Expands Global HPP737 Rights with Newsoara
TipRanks · 02/02 21:58
vTv LLC Expands Global Rights of HPP737 to Newsoara for $20 Million Upfront
Reuters · 02/02 21:19
vTv Therapeutics LLC schließt erweiterten Lizenzvertrag mit Newsoara Biopharma ab
Reuters · 02/02 21:19
Analysts Are Bullish on Top Healthcare Stocks: Pelthos Therapeutics (PTHS), Twist Bioscience (TWST)
TipRanks · 02/02 18:30
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Webull offers vTv Therapeutics Inc stock information, including NASDAQ: VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.